WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522577

CAS#: 1155419-89-8

Description: BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.

Price and Availability




BI-224436, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 522577
Name: BI-224436
CAS#: 1155419-89-8
Chemical Formula: C24H25NO4
Exact Mass: 391.1784
Molecular Weight: 391.467
Elemental Analysis: C, 73.64; H, 6.44; N, 3.58; O, 16.35

Synonym: BI-224436; BI 224436; BI224436.

IUPAC/Chemical Name: (2S)-[4-(3,4-Dihydro-2H-chromen-6-yl)-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid


InChi Code: InChI=1S/C24H25NO4/c1-24(2,3)29-22(23(26)27)18-14-25-19-9-5-4-8-17(19)21(18)16-10-11-20-15(13-16)7-6-12-28-20/h4-5,8-11,13-14,22H,6-7,12H2,1-3H3,(H,26,27)/t22-/m0/s1

SMILES Code: O=C(O)[C@H](C1=C(C2=CC(CCCO3)=C3C=C2)C4=CC=CC=C4N=C1)OC(C)(C)C

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Fader LD, Carson R, Morin S, Bilodeau F, Chabot C, Halmos T, Bailey MD, Kawai
SH, Coulombe R, Laplante S, Mekhssian K, Jakalian A, Garneau M, Duan J, Mason SW,
Simoneau B, Fenwick C, Tsantrizos Y, Yoakim C. Minimizing the Contribution of
Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors
of HIV. ACS Med Chem Lett. 2014 Apr 16;5(6):711-6. doi: 10.1021/ml500110j.
eCollection 2014 Jun 12. PubMed PMID: 24944749; PubMed Central PMCID: PMC4060926.

2: Fader LD, Malenfant E, Parisien M, Carson R, Bilodeau F, Landry S, Pesant M,
Brochu C, Morin S, Chabot C, Halmos T, Bousquet Y, Bailey MD, Kawai SH, Coulombe
R, LaPlante S, Jakalian A, Bhardwaj PK, Wernic D, Schroeder P, Amad M, Edwards P,
Garneau M, Duan J, Cordingley M, Bethell R, Mason SW, Bös M, Bonneau P, Poupart
MA, Faucher AM, Simoneau B, Fenwick C, Yoakim C, Tsantrizos Y. Discovery of BI
224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1. ACS Med Chem
Lett. 2014 Jan 22;5(4):422-7. doi: 10.1021/ml500002n. eCollection 2014 Apr 10.
PubMed PMID: 24900852; PubMed Central PMCID: PMC4027581.

3: Demeulemeester J, Chaltin P, Marchand A, De Maeyer M, Debyser Z, Christ F.
LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006
- 2014). Expert Opin Ther Pat. 2014 Jun;24(6):609-32. doi:
10.1517/13543776.2014.898753. Epub 2014 Mar 25. Review. PubMed PMID: 24666332.

4: Fenwick C, Amad M, Bailey MD, Bethell R, Bös M, Bonneau P, Cordingley M,
Coulombe R, Duan J, Edwards P, Fader LD, Faucher AM, Garneau M, Jakalian A, Kawai
S, Lamorte L, LaPlante S, Luo L, Mason S, Poupart MA, Rioux N, Schroeder P,
Simoneau B, Tremblay S, Tsantrizos Y, Witvrouw M, Yoakim C. Preclinical profile
of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimicrob
Agents Chemother. 2014 Jun;58(6):3233-44. doi: 10.1128/AAC.02719-13. Epub 2014
Mar 24. PubMed PMID: 24663024; PubMed Central PMCID: PMC4068430.

5: Karmon SL, Markowitz M. Next-generation integrase inhibitors : where to after
raltegravir? Drugs. 2013 Mar;73(3):213-28. doi: 10.1007/s40265-013-0015-5.
Review. PubMed PMID: 23413196.